Compounding Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Compounding inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Compounding Inc Today - Breaking & Trending Today

Adamis Provides Update on ZIMHI™

SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that the U.S. Food and Drug Administration . ....

United States , Robert Uhl , Dennisj Carlo , Centers For Disease , Adamis Pharmaceuticals Corporation , Drug Administration , Compounding Inc , Adamis Pharmaceuticals , Pharmaceuticals Corporation , New Drug Application , Prescription Drug User Fee Act , Chief Executive Officer , Growing Crisis , Disease Control , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , ராபர்ட் அல் , மையங்கள் க்கு நோய் , கூட்டு இன்க் , மருந்துகள் நிறுவனம் , புதியது மருந்து விண்ணப்பம் , ப்ரிஸ்க்ரிப்ஶந் மருந்து பயனர் கட்டணம் நாடகம் , தலைமை நிர்வாகி அதிகாரி , வளர்ந்து வரும் நெருக்கடி , நோய் கட்டுப்பாடு , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,

Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model

Share:
SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ( Company ) announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes COVID-19 (SARS-CoV-2), resulted in decreased inflammation in the lungs of animals treated with Tempol compared to controls. This is the first data demonstrating that Tempol, a novel antioxidant, can reduce inflammation in animals given the virus (SARS-CoV-2) that causes COVID-19. The group plans on submitting the publication to a peer review journal.
Dr. Chien-Te Kent Tseng, Professor of the Department of Microbiology and Immunology and Director of GNL s SARS/MERS/COVID-19 Laboratory at UTMB, commented on these results: In our hamster COVID-19 model, pulmonary inflammation with cellular infiltrates and hemorrhage (mild-to-moderate) is triggered by SARS-CoV-2 infection. Treatme ....

United States , Aleksandrak Drelich , Ronald Moss , Dennisj Carlo , Kempaiah Rayavara , Mark Flather , Kent Tseng , Adamis Pharmaceuticals Corporation , Compounding Inc , Adamis Pharmaceuticals , University Of Texas Medical Branch , Galveston National Laboratory , Corporate Communications , Professor Of The Department Microbiology , Stanford University , Pharmaceuticals Corporation , Texas Medical Branch , Chien Te Kent Tseng , Acute Respiratory Distress Syndrome , Placebo Controlled Study , Chief Medical Officer , Chief Executive Officer , Bi Hung Peng , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , ரொனால்ட் பாசி ,